METADATA
last updated: 2026-04-01 RT initial creation
file_name: _AI_COVID-19 Rapid Antigen Strip Tests - Comprehensive Report.md
file_date: 2026-04-01
title: FloodLAMP COVID-19 Rapid Antigen Strip Tests - Comprehensive Report
category: regulatory
subcategory: fda-policy
tags: antigen-tests, rapid-tests, lateral-flow, EUA, serial-screening, home-testing, FDA-policy, preparedness
source_file_type: md
xfile_type: NA
gfile_url: https://docs.google.com/document/d/1HSkCPwWfF13vf-9p8Kag4W8Fh3em62S-0mtDt5OpsPo
xfile_github_download_url: NA
pdf_gdrive_url: NA
pdf_github_url: NA
conversion_input_file_type: NA
conversion: AI (ChatGPT 5.4 Pro Extended)
license: CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/
tokens: 10036
words: 5866
notes: Created by ChatGPT 5.4 Pro Extended during archive preparation. **NOT HUMAN VERIFIED - MAY CONTAIN ERRORS** Comprehensive report on COVID-19 rapid antigen strip tests covering technology, EUA timeline, serial screening authorization evolution, federal mail-to-home distribution, best-documented routine screening programs (San Francisco, Liverpool, schools, healthcare, workplaces), test performance review literature, Michael Mina's policy advocacy role, and 2024-2025 multiplex/preparedness developments. 
summary_short: Comprehensive structured report on COVID-19 rapid antigen strip tests covering their technology relative to molecular testing, the EUA chronology from the first antigen authorization (May 2020) through 2024 multiplex home tests, serial screening regulatory evolution, federal COVIDTests.gov mail-to-home distribution volumes (900M+ to households), best-documented routine screening programs across municipal, school, healthcare, congregate, and first-responder settings, the Cochrane/IDSA performance review literature, Michael Mina's advocacy and the FDA policy shift, and 2024-2025 developments in multiplex testing, accessibility, and pandemic preparedness infrastructure.


CONTENT

Below is a structured report focused on **COVID-19 rapid antigen strip tests**, especially **at-home / OTC / direct-read lateral-flow tests**. I briefly note analyzer-based antigen systems where they matter for the EUA chronology, but otherwise "antigen test" below means the strip-style home test unless I say otherwise. The first FDA-authorized COVID antigen test was **Quidel's Sofia 2 SARS Antigen FIA** on **May 8, 2020**, which was analyzer-based; **Abbott BinaxNOW** on **August 26, 2020** was the first direct-read antigen card with no analyzer; and **Ellume** on **December 15, 2020** was the first **over-the-counter fully at-home** COVID test. ([U.S. Food and Drug Administration][1])

## Executive takeaways

- **Technologically**, COVID strip antigen tests are lateral-flow immunoassays that detect viral proteins, typically from a nasal swab, and trade some analytic sensitivity for speed, simplicity, low cost, and decentralized use. Molecular tests detect viral RNA and remain more sensitive. ([U.S. Food and Drug Administration][2])
- **Historically**, before COVID, rapid antigen tests already existed for respiratory viruses, but clinical guidelines were increasingly favoring rapid molecular testing for diagnosis because of higher sensitivity, especially in hospitalized patients. COVID changed antigen's role from a niche or secondary diagnostic tool into a mass **public-health screening tool** used at home, in schools, in workplaces, and in municipal programs. ([CDC][3])
- **Regulatorily**, FDA's path moved from professional/instrument-based antigen testing in spring 2020, to direct-read cards in late summer 2020, to OTC home tests in December 2020, and then to a broad serial/repeat-testing framework in 2021-2022. FDA milestone reports listed **30 antigen EUAs by July 2021**, **37 by November 2021**, **41 by December 2021**, and **59 by January 2023**; later 2023-2024 authorizations, especially COVID/flu combo home tests, pushed the cumulative total higher. ([U.S. Food and Drug Administration][4])
- **Operationally**, the strongest routine-screening exemplars were not one-off performance studies but organized programs with clear action pathways: Liverpool's city/community and key-worker pilots, English and U.S. school "test-to-stay" programs, San Francisco shelter/community programs, and healthcare workforce continuity programs. The literature for **dedicated fire/police/EMS-only** serial screening is much thinner than for schools, shelters, and hospitals. ([PMC][5])
- **Post-2023**, antigen testing did not disappear; it shifted toward **multiplex COVID/flu home tests**, accessibility improvements, data-reporting infrastructure, and reuse of RADx/ITAP capacity for broader preparedness. At the same time, GAO concluded in 2025 that HHS still lacked a sufficiently coordinated national diagnostic testing strategy for future pandemic threats. ([nibib.nih.gov][6])

## 1) What antigen strip tests are, and where they sit relative to molecular testing

At-home COVID antigen tests are lateral-flow devices: a nasal swab is mixed in buffer, the sample flows across the strip, and antibodies on the test capture viral antigen to generate a visible line. They are fast and portable and can be self-administered. Their basic tradeoff is lower analytic sensitivity than molecular methods: the 2023 *Nature Reviews Bioengineering* review summarized rapid antigen tests as typically detecting virus around roughly **10^5 to 10^6 genome copies/mL**, whereas RT-PCR can detect around **1 to 100 copies/mL**. FDA's current consumer guidance likewise says at-home antigen tests are less likely than molecular tests to detect SARS-CoV-2, especially early in infection or in asymptomatic people. ([Nature][7])

**Before COVID**, respiratory diagnostics were already moving toward molecular testing in clinical care. CDC's influenza testing overview says IDSA recommends **rapid influenza molecular assays over rapid influenza diagnostic tests (RIDTs)** for outpatients, and molecular assays for hospitalized patients. A 2019 systematic review of rapid respiratory-virus molecular tests noted that rapid molecular assays were displacing older rapid antigen assays because of superior sensitivity, while the latter had traditionally offered speed and convenience at lower performance. ([CDC][3])

**During COVID**, that positioning changed. Molecular tests remained the most sensitive reference method, but antigen strip tests became valuable because they were cheap, fast, easy to deploy, and repeatable. That made them unusually well suited to **screening for likely infectious people in real time**, especially when the operational question was "should this person go to school, work, a shelter, or an event today?" rather than "what is the most sensitive clinical diagnostic answer possible?" FDA, Cochrane, and IDSA all converge on the same bottom line: a single antigen test is weaker than molecular testing, but repeat testing improves performance and the tools are useful when immediacy matters. ([U.S. Food and Drug Administration][2])

**After the acute emergency phase**, antigen's role narrowed but did not vanish. The home-testing market increasingly moved toward **COVID/flu combination tests**, and the regulatory system began to move some products from emergency-only pathways toward traditional authorization. Molecular home tests remained a smaller, often instrument-assisted segment, while strip tests remained the dominant low-friction consumer product. ([U.S. Food and Drug Administration][8])

## 2) EUA timeline for rapid antigen strip tests

A concise chronology:

- **May 8, 2020:** Quidel Sofia 2 SARS Antigen FIA became the **first COVID antigen EUA**. This was a professional, analyzer-based assay, not a home strip test. ([U.S. Food and Drug Administration][1])
- **August 26, 2020:** Abbott **BinaxNOW COVID-19 Ag Card** became the **first direct-read antigen card** that did not require an instrument. This is the most important "bridge" product between professional antigen testing and the consumer/home strip era. ([U.S. Food and Drug Administration][9])
- **December 15, 2020:** **Ellume COVID-19 Home Test** became the **first OTC fully at-home COVID test** in the U.S. ([U.S. Food and Drug Administration][10])
- **December 16, 2020:** **BinaxNOW COVID-19 Ag Card Home Test** became the first **prescription** at-home antigen test. ([U.S. Food and Drug Administration][11])
- **2021-2022:** OTC strip tests proliferated rapidly: FDA milestone summaries reported **30 antigen tests by July 19, 2021**, **37 by November 4, 2021**, **41 by December 2021**, and **59 by January 2023**. ([U.S. Food and Drug Administration][4])
- **2023-2024:** additional antigen EUAs continued, including newer home tests and then a burst of **home COVID/flu combination antigen tests** in 2024, including ITAP-supported products from **SEKISUI, OSANG, CorDx, Wondfo, iHealth, and Watmind**. ([U.S. Food and Drug Administration][12])

One important caveat: FDA's public milestone summaries usually reported **all antigen EUA products**, not a clean lifetime subtotal for **strip-style home tests only**. So the most defensible way to describe the strip/home trajectory is by the first major authorizations and the milestone counts above, rather than by a single official strip-only cumulative number. FDA's current public pages are organized as **live product rosters** (OTC list, antigen EUA list), not as one tidy historical strip-only counter. ([U.S. Food and Drug Administration][12])

## 3) Serial screening: when it emerged, and what changed

This was a major regulatory evolution. In the earlier phase of the pandemic, antigen products were often authorized with narrower symptomatic or supervised use cases. FDA's milestone summaries show the number of **antigen tests specifically authorized for serial screening** growing from **6** in **April 2021**, to **12** in **July 2021**, to **23** in **December 2021**, and **44** by **January 24, 2023**. ([U.S. Food and Drug Administration][13])

The turning point came in **August-November 2022**. FDA said the NIH/FDA/U. Mass "**Test Us At Home**" serial-testing work showed that repeat testing over multiple days improves performance, including for asymptomatic infection. FDA first recommended repeat testing after any negative at-home antigen result on **August 11, 2022**, and then on **November 1, 2022** revised the authorized uses and labeling for **all currently authorized SARS-CoV-2 antigen tests** to incorporate repeat/serial testing after a negative result. FDA's current consumer pages now say that **all FDA-authorized at-home COVID antigen tests are authorized for repeat testing**. ([U.S. Food and Drug Administration][14])

So, historically, "authorized for serial screening" versus "not yet authorized for serial screening" was a real product-level distinction in 2021 and early 2022. **Practically, today, it is much less important**, because FDA harmonized the category. The current FDA OTC page shows representative strip tests such as **BinaxNOW Self Test, CareStart, Flowflex, QuickVue, ImmuView**, and newer combo tests such as **CorDx TyFast** and **Watmind Speedy Swab** all carrying serial-testing instructions, usually **2 tests over 3 days** for symptomatic users and **3 tests over 5 days** for asymptomatic users. ([U.S. Food and Drug Administration][8])

## 4) Free federal antigen tests shipped to homes: volume, periods, and use

The mail-to-home program was one of the clearest signals that antigen strip tests had moved from fringe to core federal public-health infrastructure. On **January 14, 2022**, the White House announced the purchase of **1 billion free at-home tests**; **COVIDTests.gov** went live on **January 18, 2022** with an initial allowance of **4 tests per household**. USPS later reported that in the first **6 hours** the site received orders for **42 million tests**. Households then got **4 more tests in March 2022** and **8 more beginning in April 2022**. ([The American Presidency Project][15])

The scale-up was enormous. USPS said that by **March 2, 2022** it had shipped **more than 270 million tests** in **more than 68 million packages**. The White House said that by **May 17, 2022** approximately **350 million** free tests had been delivered. USPS's FY2022 reporting said that during **2022 alone** it delivered **more than 668 million tests** in about **167 million packages** to **more than 78 million households**. ASPR testified in **February 2023** that more than **720 million at-home tests** had been delivered to homes since the effort began. ([USPS][16])

The federal home-order program restarted later. USPS said on **September 28, 2023** that households could again order **4 tests**, and that more than **750 million tests** had already been shipped in earlier rounds. On **October 2, 2024**, USPS said the **seventh round** had begun and that since the program started, ASPR and USPS had distributed about **900 million tests to households**. That "household" figure is distinct from the **larger all-channels number**: by **March 2024**, HHS/AP reported more than **1.8 billion free tests** had been distributed through **COVIDTests.gov plus direct channels** such as schools, long-term-care settings, food banks, community health centers, and other partners. ([USPS Employee News][17])

In terms of actual household use, CDC's 2023 MMWR on COVIDTests.gov reported **93.8%** household awareness, **59.9%** of households having ordered kits, and more than **40 million households** using at least one kit. Among people who had tested in the previous six months, **38.3%** had used a COVIDTests.gov kit. That is strong evidence that the mail program changed real-world testing behavior, not just procurement statistics. ([CDC][18])

## 5) Routine screening programs: the best exemplars

This is the most important section for the question. The clearest lesson from the literature is that antigen strip tests worked best in **programmatic settings** when three things were true: the result was available immediately, a positive result triggered a specific operational response, and the program repeated testing frequently enough to compensate for lower single-test sensitivity. The best evidence clusters around **municipal/community pilots, schools, healthcare/workplaces, and congregate settings**. Published evidence for stand-alone **fire/police/EMS** screening is much thinner. ([Nature][7])

### A. San Francisco community and congregate-setting programs

**1) UCSF / Chan Zuckerberg Biohub / Unidos en Salud -- San Francisco community-site studies.**
The best-known San Francisco field-performance paper is the **Pilarowski et al.** community/public-plaza work. In one widely cited community study of **3,302** people tested by BinaxNOW and PCR, the rapid assay had **100% sensitivity at Ct <30**, **98.5% at Ct <35**, and **89% overall**, with **99.9% specificity**. The operational point was important: rapid results enabled **immediate public-health action**, not just lab confirmation. This was not a daily serial program per person, but it was one of the most influential demonstrations that strip antigen tests could be used effectively in a real community setting, including among asymptomatic people. ([OUP Academic][19])

A later **Omicron-wave** follow-up from the same San Francisco community ecosystem tested **731** people in January 2022; **296** were RT-PCR positive and **98.9%** were Omicron. BinaxNOW detected **95.2%** of RT-PCR positives with **Ct <30**, **82.1%** with **Ct <35**, and **65.2%** of all PCR positives. That study is important because it showed why repeated antigen testing remained useful even as people worried about variant performance: the tests still detected most high-viral-load cases quickly, but a single negative was not enough. ([PubMed][20])

**2) San Francisco congregate homeless shelters.**
The most programmatic San Francisco serial-screening exemplar is the shelter work: **rapid and frequent BinaxNOW testing** was offered to residents and staff at **10 of 12 shelters** between **January 15 and February 19, 2021**. About **half** of eligible residents/staff tested at least once; **2.2%** were positive; **three outbreaks** were detected, but none exceeded **five cases**. The paper's real value is implementation detail: it shows how a repeated antigen program can be embedded into a public-health response system for a high-risk congregate setting. ([PubMed][21])

**Why San Francisco matters.**
If I had to summarize the San Francisco contribution in one line, it is this: those UCSF/Biohub/Unidos en Salud studies did not prove that antigen tests were "as good as PCR." They showed something more operationally important -- that rapid strip tests could identify many of the most infectious people **fast enough to change behavior immediately**, especially when paired with repeat testing and public-health follow-up. ([OUP Academic][19])

### B. Liverpool: the strongest municipal and first-responder-adjacent exemplar

**1) City-wide voluntary community screening.**
Liverpool's 2020-2021 lateral-flow program is arguably the single strongest **municipal-scale** exemplar. A BMJ synthetic-control study found that Liverpool's city-wide asymptomatic rapid antigen pilot was associated with a **43% reduction** in COVID-related hospital admissions during its initial intensive phase and a **25% overall reduction** over the full evaluation period before national rollout. Separate Liverpool cohort work also evaluated performance among asymptomatic adults across **48 testing sites**. ([PMC][5])

**2) SMART Release / daily testing for key workers.**
For specific interest in **fire, police, ambulance, and frontline continuity**, Liverpool is especially important. The **SMART Release** pilot evaluated **daily lateral-flow testing** as an alternative to quarantine for close contacts who were key workers in **fire, police, NHS, and local government organizations**. The protocol used **daily LFTs up to day 7 after exposure plus a PCR around day 6-7**. The published study reported high compliance and concluded that daily contact testing helped sustain service continuity; Liverpool's own evaluation reported about **8,292 workdays saved** and described the service as a "lifeline." This is the strongest documented fire/police-related exemplar found. ([ResearchGate][22])

**Bottom line on Liverpool.**
Liverpool is the clearest proof-of-concept that antigen screening could operate at **municipal** scale and that **daily testing** could be used not just for case-finding, but to preserve essential services without automatically sending large numbers of exposed but uninfected workers home. ([PMC][5])

### C. Schools: the richest routine-screening literature

**1) English secondary schools and colleges -- randomized trial.**
The highest-quality school evidence is the English cluster-randomized trial of **201 schools**. Close contacts in intervention schools were offered **daily lateral-flow testing** as an alternative to **10-day self-isolation**. **2,432 of 5,763** eligible contacts participated. The trial found that daily contact testing was **non-inferior** to self-isolation for control of transmission, with similar symptomatic infection rates. All schools also followed a national policy of **twice-weekly asymptomatic LFD testing**, so the program sat inside a broader antigen-screening environment. ([PMC][23])

**2) North Carolina "test-to-stay."**
A strong U.S. school exemplar is the North Carolina **Test-to-Stay** study. Participants underwent serial rapid antigen testing for up to 7 days after exposure. The analysis reported **367 participants**, **883 serial rapid antigen tests** with analyzable results from **357 participants**, a **1.7% secondary attack rate**, **no tertiary cases**, and **1,628 school days saved** -- about **92%** of days that otherwise would have been missed. This is one of the cleanest U.S. demonstrations that serial antigen testing could keep exposed students/staff in school safely. ([PubMed][24])

**3) New South Wales, Australia -- ecological "test-to-stay" study (2024).**
This is useful because it is later and larger. In **293 schools**, **9,887** people reported at least one RAT; the program preserved **30,535 school days**. The secondary attack rate in RAT schools was **3.4%**, versus **2.8%** in non-RAT schools, and the study concluded that RAT use preserved in-person learning **without a significant increase** in SAR. It is not a randomized trial, but it is a valuable real-world systems paper. ([PubMed][25])

**4) Los Angeles County high school athletes -- daily testing.**
For a very operational daily-screening example, LA County's public high-school sports program is strong. Across **5 high schools**, **506 student athletes** and **50 coaches/staff** participated. Indoor sports such as basketball, wrestling, and cheerleading were tested **daily** before practice/competition; soccer was tested weekly. Across **7,594** rapid antigen tests, the program detected **one** positive athlete, isolated him quickly, and reported **no onward transmission** to athletes or staff. This is a good template for high-risk-activity screening rather than general classroom screening. ([PMC][26])

### D. Healthcare and workplaces

**1) California forensic psychiatric inpatient hospitals -- daily staff testing.**
This is one of the largest pure daily workforce-screening examples found. Across **5 hospitals** from **December 13, 2020 to April 30, 2021**, a daily antigen testing program for healthcare personnel administered **471,023 tests** and detected **449 positives**. Even if the paper is less famous than school studies, it is a major scale example of sustained daily screening. ([PubMed][27])

**2) Acute hospital and ambulance trusts in England -- daily contact testing.**
This is the best **ambulance-related** serial-screening paper found. A pilot at **four acute hospital trusts and one ambulance trust** used **7-day daily lateral-flow testing** for healthcare-worker contacts. Among **138** identified contacts, **111** consented; **82** completed the program without interruption; only **one** participant was positive on both LFD and PCR, **three** were PCR-positive/LFD-negative, no transmission incidents were detected, and an estimated **729 workdays of absence** were averted. ([UK Health Security Agency][28])

**3) Canada -- large-scale workplace screening system.**
The Canadian Creative Destruction Lab Rapid Screening Consortium paper is one of the best implementation papers on routine workplace screening. Between **January 11 and June 25, 2021**, the program deployed **321,905** RATs across **73 organizations**, identified **473 antigen-positive/PCR-confirmed asymptomatic** cases, and estimated roughly **1 false positive per 4,300 RATs**. The authors explicitly frame it as a **frequent**, standardized, scalable workplace screening system. ([PMC][29])

**4) Singapore acute-hospital laboratory surveillance.**
A smaller but instructive operational example comes from Singapore, where a hospital lab with **161 staff** underwent **twice- and thrice-weekly** antigen testing as routine surveillance from **August 2021** onward. No cases were detected with either regimen. It is not a large effect-size paper, but it is a useful example of a near-daily/very frequent staff-surveillance model in a critical service environment. ([OUCI][30])

### E. What was found on EMS / fire / police / ambulance specifically

The literature here is **surprisingly sparse** compared with schools, shelters, and hospitals. The strongest documented first-responder-adjacent evidence found was **Liverpool SMART Release**, which explicitly included **fire and police**, and the England **hospital/ambulance-trust** daily-contact-testing pilot. Beyond that, much of the EMS literature is about **paramedics using antigen tests on patients** or about prehospital triage/admission pathways, not about routine serial screening of EMS staff themselves. The evidence base for dedicated U.S. fire/police/ambulance screening programs appears much thinner than the evidence base for schools and healthcare settings. ([ResearchGate][22])

## 6) The review literature on antigen-test performance

The **Cochrane review** remains the most important umbrella reference. Its 2022 version, updated again in 2025, concluded that rapid antigen tests are **most accurate in people with symptoms**, especially **during the first week of illness**, and that a negative result **does not rule out infection**. That remains the single best starting point for a high-level performance section. ([PMC][31])

For a clinically oriented companion, the **IDSA 2022 guideline** quantified pooled antigen sensitivity at **81%** in symptomatic people overall, **89%** when testing occurred within **5 days** of symptom onset, and **54%** after day 5. FDA's current consumer guidance uses the same practical conclusion: antigen tests are less accurate than molecular tests, and **negative results should be repeated**. ([Infectious Diseases Society of America][32])

For screening programs specifically, the **Walsh et al.** rapid review is useful because it focused on screening and surveillance of asymptomatic individuals and concluded that the evidence base was still heterogeneous and limited in the early period. And for a broader design-and-operations view, the 2023 *Nature Reviews Bioengineering* review is helpful because it explains why lateral-flow tests are attractive in population screening even when they are analytically weaker than PCR: they align better with **speed, repeatability, and decentralized use**. ([PMC][33])

## 7) Michael Mina, activism, FDA "reluctance," and the policy shift

Michael Mina's role was genuinely important. In **2020**, he argued publicly and in academic writing that the question for public-health screening was not "is this test as analytically sensitive as PCR?" but rather "can this cheap, rapid test identify people when they are most infectious, and can it be repeated frequently enough to interrupt transmission?" In August 2020, he publicly urged federal approval of low-cost, frequent paper-strip tests and argued they could function "**akin to a vaccine**" by breaking transmission chains. His NEJM and later Lancet pieces made the same conceptual case in more formal form. ([Harvard Gazette][34])

On the assessment that FDA was reluctant: **partly yes**. The timeline supports that view. FDA had an antigen EUA in **May 2020**, but it was analyzer-based; the first direct-read card did not arrive until **late August 2020**; the first OTC fully at-home test arrived only in **mid-December 2020**; and broad serial-screening labeling did not mature until **2021-2022**, with the major harmonizing revision only in **November 2022**. That is real evidence of a regulatory system that initially prioritized higher-sensitivity, clinically legible testing pathways. ([U.S. Food and Drug Administration][1])

But the delay should not be reduced to simple bureaucratic inertia. There was also a **real scientific dispute** about asymptomatic performance, false reassurance, and whether people would misuse a negative antigen result as a license to behave unsafely. Cochrane and IDSA later still found materially lower single-test sensitivity than molecular testing, especially in asymptomatic or early infection, and prominent critics in BMJ argued that policy enthusiasm for lateral-flow testing sometimes outran the evidence. The fairest reading is that Mina and allied advocates **materially changed the policy conversation**, but they did so in the context of a genuine unresolved scientific and implementation debate. ([PMC][31])

The political shift became obvious by early **2022**. President Biden said on **January 19, 2022**, "**Should we have done more testing earlier? Yes. But we're doing more now,**" noting the expansion from zero at-home tests a year earlier to hundreds of millions on the market and the launch of **1 billion free home tests**. In a White House briefing on **February 16, 2022**, Dr. Tom Inglesby said the administration had recognized the role of rapid tests, used the **Defense Production Act**, invested **$3 billion** to expand and accelerate manufacturing, and created a faster pathway for manufacturers to seek FDA authorization. ([The American Presidency Project][35])

The overall judgment is that Mina's activism was **not the sole cause** of the policy shift, but it was probably one of the most important pieces of **agenda-setting**. The later expansion also required manufacturing investment, White House prioritization, operational studies from places like San Francisco and Liverpool, and the NIH/FDA serial-testing evidence that underpinned the 2022 repeat-testing revisions. ([Harvard Gazette][34])

## 8) What happened in 2024-2025, and what this means for preparedness now

The post-2023 story is not "antigen tests faded away." It is better described as **institutionalization and repurposing**.

First, 2024 saw a **multiplex home-test wave**. NIBIB's RADx Tech timeline shows a burst of ITAP-supported FDA authorizations for **COVID/flu A/B antigen tests**, including **SEKISUI (Feb 29, 2024)**, **OSANG OTC (Apr 3, 2024)**, **CorDx OTC (Apr 5, 2024)**, **Wondfo OTC (Apr 30, 2024)**, **iHealth OTC (May 7, 2024)**, and **Watmind OTC (May 24, 2024)**. That is a clear sign that antigen testing's "afterlife" is respiratory multiplexing, not just stand-alone COVID strips. ([nibib.nih.gov][6])

Second, **ITAP and RADx did not disappear**. NIBIB now explicitly says it is building on RADx Tech and ITAP infrastructure "to address a range of respiratory diseases and other health challenges," and is using ITAP mechanisms to accelerate validation, regulatory authorization, and commercialization of **hepatitis B surface antigen point-of-care tests**. NIH's 2025 RADx programs page still describes RADx Tech as speeding development, validation, and commercialization of **point-of-care and home-based tests**. ([nibib.nih.gov][36])

Third, the federal government has tried to preserve not just products, but **capabilities**. NIH's 2024 RADx white paper says RADx Tech created U.S. capacity for **more than 7.8 billion tests and test products**, shifted testing from labs to **home and point-of-care**, and continues to develop **multiplex respiratory** and **accessible home tests**. NIBIB's FY2025 Congressional Justification says RADx Tech **continues** to speed commercialization of innovative point-of-care and accessible home-based tests for COVID testing. ([National Institutes of Health (NIH)][37])

Fourth, preparedness now includes **accessibility and data infrastructure**, not just assay chemistry. The RADx Tech Accessibility Initiative's 2025 case-study paper says the program not only improved accessibility of COVID home tests, but also created best-practice frameworks for future accessible consumer diagnostics. FDA's 2024 digital diagnostics page says non-lab-based testing is expected to continue expanding, and specifically notes that ITAP helped authorize at-home tests through standardized evaluation protocols and reporting mechanisms. FDA is also building data and software infrastructure so OTC/POC diagnostics can feed into surveillance and regulatory science beyond COVID. ([PMC][38])

Fifth, there is still a preparedness gap. GAO's **June 2025** report said HHS still lacked a sufficiently coordinated national approach for diagnostic testing for future pandemic threats and recommended a **national diagnostic testing strategy** plus a standing **testing forum** with relevant stakeholders. That is an important corrective to any narrative that the U.S. "solved" pandemic testing just because the antigen market matured. ([GAO][39])

A fair synthesis for 2024-2025 is therefore: **antigen testing has been retained as a preparedness asset, but mainly as part of broader home/POC diagnostic infrastructure -- multiplexing, accessibility, digital reporting, and reusable regulatory/deployment machinery -- rather than as a stand-alone COVID-only emergency program.** ([nibib.nih.gov][36])

## 9) The papers to pull first

For the program section, these are the highest-yield references:

- **Pilarowski et al.** on **BinaxNOW at a San Francisco community/public-plaza site** -- key early UCSF/Biohub field-performance paper with immediate public-health response framing. ([OUP Academic][19])
- **Schrom et al.** on **BinaxNOW vs PCR during the Omicron surge in San Francisco** -- strong follow-up on variant-era community use. ([PubMed][20])
- **"Implementation of rapid and frequent SARS-CoV-2 antigen testing and response in congregate homeless shelters"** -- best congregate-setting implementation exemplar. ([PubMed][21])
- **Zhang et al., BMJ 2022** on **Liverpool city-wide asymptomatic testing** -- best municipal impact paper. ([PMC][5])
- **Marsden et al., EClinicalMedicine 2022** on **Liverpool SMART Release for key workers** -- strongest fire/police/NHS/local-government serial-testing exemplar. ([ResearchGate][22])
- **Young et al., Lancet 2021** on **daily contact testing in English secondary schools** -- strongest randomized school study. ([PMC][23])
- **Campbell et al., Pediatrics 2022** on **North Carolina Test-to-Stay** -- strongest U.S. school implementation paper. ([PubMed][24])
- **Bow et al., Public Health 2022** on **daily testing in acute hospital and ambulance trusts** -- best ambulance-trust/healthcare continuity paper. ([UK Health Security Agency][28])
- **California daily HCP program** -- best large-scale pure daily staff-screening example. ([PubMed][27])
- **Canadian workplace rapid-screening system** -- best large-scale workplace implementation paper. ([PMC][29])

For the performance/review section, anchor on **Cochrane**, then add **IDSA**, the **Walsh screening review**, and the 2023 **Nature Reviews Bioengineering** piece for the technology and policy interpretation. ([Cochrane Library][40])

## Bottom line

The core historical arc is: **antigen strip tests started as a lower-sensitivity alternative to molecular testing, became a mass public-health screening tool during COVID, and have now settled into a preparedness role centered on home use, multiplex respiratory testing, accessibility, and fast decentralized deployment.** The best evidence for their value comes less from "single-test accuracy" in the abstract than from **programs** that used them repeatedly and acted on results immediately. The single-sentence summary: **antigen strip tests were most useful when the goal was fast detection of likely infectious people and rapid operational action, not when the goal was to replace molecular testing as the most sensitive clinical diagnostic method.** ([U.S. Food and Drug Administration][2])

A natural next step would be an **annotated bibliography** organized by **schools, workplaces, municipal/community pilots, shelters, first responders, and regulation**.

## Follow-up: GAO assessment of the need for a national pandemic testing strategy

**U.S. Government Accountability Office (GAO). *Public Health Preparedness: HHS Needs a Coordinated National Approach for Diagnostic Testing for Pandemic Threats*. GAO-25-106980. Published June 4, 2025.** ([GAO][39])

The exact GAO product page says HHS had **not established either** of the two central mechanisms GAO thought were needed before the next emergency: **a national diagnostic testing strategy** and **a diagnostic testing coordinating group/forum**. GAO's recommendation section then formally recommends that HHS create both and keep them updated/meeting regularly. ([GAO][39])

### What the 2025 GAO report actually concluded

The conclusion was not just that HHS was missing a document. GAO's finding was broader: the U.S. needed a **coordinated national approach** to diagnostic testing for future pandemic threats, and HHS had not yet put the needed coordination architecture in place. GAO said the expert roundtable it convened produced **nearly 100 suggested actions** across test development, deployment, guidance, and data collection, but that two cross-cutting actions stood out above the rest:

1. a **national diagnostic testing strategy**, and
2. a **diagnostic testing coordinating forum** with all the relevant partners. ([GAO][39])

GAO's summary explains why those two actions mattered. In its words, a national strategy would set **clear roles and responsibilities**, improve collaboration, and help manage risks such as differing resources and cooperation across jurisdictions. A forum would bring together HHS, other federal agencies, jurisdictions, the private sector, academia, and nonprofits to coordinate before and during emergencies and to maintain the strategy over time. ([GAO][39])

### Why GAO reached that conclusion

The report's reasoning is rooted in GAO's retrospective view of the COVID testing response. GAO says that during COVID, HHS **"struggled to lead the nation's testing efforts,"** and it explicitly ties that to the need for close coordination with public and private stakeholders. GAO also notes that this testing experience was **one reason** it had already placed HHS's leadership and coordination of public health emergencies on GAO's **High Risk List** in 2022. ([GAO][39])

More specifically, GAO says HHS faced major challenges in four areas during COVID:

- developing accurate tests quickly,
- deploying tests,
- issuing clear guidance for test use, and
- collecting complete testing data. ([GAO][39])

So the 2025 report is less a complaint about one missed planning document and more a diagnosis of a **systemic coordination problem**: testing in a pandemic depends on regulators, public-health agencies, commercial manufacturers, labs, hospitals, states, localities, and data-reporting systems all moving together. GAO's conclusion was that HHS still had not built the standing structure needed to align those actors before the next crisis. ([GAO][39])

### How this fits into GAO's longer-running criticism of HHS testing policy

The 2025 report did not come out of nowhere. It builds directly on GAO's **January 2021** COVID report, **GAO-21-265**, where GAO had already found that HHS had **not issued a comprehensive and publicly available national COVID-19 testing strategy**. In that earlier report, GAO said stakeholders involved in the response either did not know such a strategy existed or did not clearly understand it. GAO also found that HHS's testing strategy documents only partially met GAO's six characteristics of an effective national strategy. ([GAO][41])

Those six characteristics were:

- clear purpose, scope, and methodology;
- problem definition and risk assessment;
- goals, objectives, activities, and performance measures;
- resources, investments, and risk management;
- organizational roles, responsibilities, and coordination; and
- integration and implementation. ([GAO][41])

GAO's 2021 criticism was concrete. It said HHS's testing documents did not consistently define benchmarks, did not always clearly define the problem and risks, and gave only limited information on future resource needs. It also noted that some testing-strategy implementation documents had not been made public, which made it harder for stakeholders to coordinate around a shared plan. ([GAO][41])

That is the key context for reading the 2025 line about a lack of coordination. GAO had already been arguing since 2021 that HHS lacked a sufficiently comprehensive, public, and operationally clear testing strategy. The 2025 report extends that logic from **COVID-specific testing** to **future pandemic threats generally** and adds a second institutional fix: not just a strategy, but also a permanent **forum** to coordinate the ecosystem. ([GAO][41])

### What GAO wanted HHS to do

The 2025 report made **four recommendations** to HHS:

- develop a national diagnostic testing strategy for infectious diseases with pandemic potential,
- update it periodically with lessons learned and exercise results,
- establish a national diagnostic testing forum or expand an existing group, and
- ensure that forum meets regularly before and during emergencies. ([GAO][39])

So the practical meaning of the conclusion is: GAO believed the federal government still had not converted the lessons of COVID testing into a durable preparedness system. In GAO's view, preparedness required both a **strategy layer** and a **governance layer**. The strategy defines roles, priorities, risks, and measures; the forum keeps the public and private testing ecosystem aligned as conditions change. ([GAO][39])

### Significance

This is an important report because it says the U.S. testing problem was not only about having enough assays or manufacturing capacity. GAO is effectively arguing that the bigger weakness was **coordination under uncertainty**: who leads, who shares data, who updates guidance, how federal and nonfederal actors align, and how the system adjusts when the threat or technology changes. That framing is especially relevant to antigen tests, because those products depend heavily on coordination across regulation, manufacturing, distribution, public guidance, and data/reporting. That last sentence is synthesis based on GAO's documented emphasis on development, deployment, guidance, and data collection. ([GAO][39])

## References
[1]: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-antigen-test-help-rapid-detection-virus-causes "FDA - First Antigen Test Authorization"
[2]: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/understanding-home-otc-covid-19-antigen-diagnostic-test-results "FDA - Understanding Home OTC COVID-19 Antigen Test Results"
[3]: https://www.cdc.gov/flu/hcp/testing-methods/index.html "CDC - Influenza Testing Methods"
[4]: https://www.fda.gov/media/137005/download "FDA - COVID-19 Milestone Summary"
[5]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9682337/ "PMC - Liverpool City-Wide Asymptomatic Testing"
[6]: https://www.nibib.nih.gov/programs/radx-tech-program/timeline "NIBIB - RADx Tech Program Timeline"
[7]: https://www.nature.com/articles/s44222-022-00007-3 "Nature Reviews Bioengineering - Rapid Antigen Tests Review"
[8]: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/home-otc-covid-19-diagnostic-tests "FDA - Home OTC COVID-19 Diagnostic Tests"
[9]: https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-authorizes-first-diagnostic-test-where-results-can-be-read-directly-testing-card "FDA - BinaxNOW Authorization"
[10]: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-antigen-test-first-over-counter-fully-home-diagnostic "FDA - Ellume OTC Home Test Authorization"
[11]: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-december-16-2020 "FDA - BinaxNOW Home Test Authorization"
[12]: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2 "FDA - Antigen Diagnostic Tests EUA List"
[13]: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-april-2-2021 "FDA - COVID-19 Update April 2021"
[14]: https://www.fda.gov/media/162799/download "FDA - Serial Testing Labeling Revision"
[15]: https://www.presidency.ucsb.edu/documents/fact-sheet-the-biden-administration-begin-distributing-home-rapid-covid-19-tests-americans "White House - Free Home Test Distribution Fact Sheet"
[16]: https://about.usps.com/newsroom/national-releases/2022/0302-usps-delivered-more-than-270million-covid-19-test-kits.htm "USPS - 270 Million Test Kits Delivered"
[17]: https://news.usps.com/2023/09/28/covid-19-tests-4/ "USPS Employee News - COVID-19 Tests Round 4"
[18]: https://www.cdc.gov/mmwr/volumes/72/wr/mm7216a6.htm "CDC MMWR - COVIDTests.gov Household Use"
[19]: https://academic.oup.com/cid/article/73/9/e3098/6052342 "Pilarowski et al. - BinaxNOW Community Testing"
[20]: https://pubmed.ncbi.nlm.nih.gov/35286144/ "Schrom et al. - BinaxNOW Omicron Performance"
[21]: https://pubmed.ncbi.nlm.nih.gov/35271622/ "SF Congregate Homeless Shelter Antigen Testing"
[22]: https://www.researchgate.net/publication/361841676_Daily_testing_of_contacts_of_SARS-CoV-2_infected_cases_as_an_alternative_to_quarantine_for_key_workers_in_Liverpool_A_prospective_cohort_study "Marsden et al. - Liverpool SMART Release Key Workers"
[23]: https://pmc.ncbi.nlm.nih.gov/articles/PMC8439620/ "Young et al. - English Schools Daily Contact Testing Trial"
[24]: https://pubmed.ncbi.nlm.nih.gov/35437593/ "Campbell et al. - NC Test-to-Stay"
[25]: https://pubmed.ncbi.nlm.nih.gov/38924953/ "NSW Australia Test-to-Stay Ecological Study"
[26]: https://pmc.ncbi.nlm.nih.gov/articles/PMC10032046/ "LA County High School Athletes Daily Testing"
[27]: https://pubmed.ncbi.nlm.nih.gov/35196037/ "California Forensic Psychiatric Hospitals Daily Staff Testing"
[28]: https://researchportal.ukhsa.gov.uk/en/publications/an-evaluation-of-a-pilot-of-daily-testing-of-sars-cov-2-contacts- "Bow et al. - Hospital and Ambulance Trust Daily Testing"
[29]: https://pmc.ncbi.nlm.nih.gov/articles/PMC8880770/ "Canadian Workplace Rapid Screening Consortium"
[30]: https://ouci.dntb.gov.ua/en/works/7X13kDp4/ "Singapore Hospital Lab Staff Antigen Surveillance"
[31]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9305720/ "Cochrane Review - Rapid Antigen Tests"
[32]: https://www.idsociety.org/practice-guideline/covid-19-guideline-antigen-testing/ "IDSA - COVID-19 Antigen Testing Guideline"
[33]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9111057/ "Walsh et al. - Screening and Surveillance Review"
[34]: https://news.harvard.edu/gazette/story/2020/08/cheap-daily-covid-tests-could-be-akin-to-vaccine/ "Harvard Gazette - Michael Mina Daily Testing Advocacy"
[35]: https://www.presidency.ucsb.edu/documents/the-presidents-news-conference-1269 "Biden Press Conference Jan 2022"
[36]: https://www.nibib.nih.gov/programs/radx-innovation-funnel "NIBIB - RADx Innovation Funnel"
[37]: https://www.nih.gov/sites/default/files/2024-12/RADx-Tech-White-Paper-March-2024.pdf "NIH RADx Tech White Paper 2024"
[38]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12235081/ "RADx Tech Accessibility Initiative Case Study"
[39]: https://www.gao.gov/products/gao-25-106980 "GAO 2025 - National Diagnostic Testing Strategy"
[40]: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013705.pub4/full "Cochrane Library - Rapid Antigen Tests Full Review"
[41]: https://www.gao.gov/assets/720/712242.pdf "GAO-21-265 - COVID-19 National Testing Strategy"